Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lytix Biopharma AS ( (DE:6BG) ) just unveiled an announcement.
Lytix Biopharma AS has called its Annual General Meeting for 14 April 2026 in Oslo, where shareholders will vote on the 2025 annual report, board elections, remuneration for the Board and Nomination Committee, and a renewed authorization to increase share capital for the company’s option program. The board is proposing that no dividend be paid for the 2025 financial year, underscoring a continued focus on reinvesting resources into its clinical development of oncolytic peptide-based immunotherapies, and AGM materials are available on the company’s website with shareholders asked to register or submit proxies by 10 April 2026.
More about Lytix Biopharma AS
Lytix Biopharma AS is an Oslo-based clinical-stage biotechnology company focused on developing novel cancer immunotherapies. Its pipeline is built around oncolytic peptides that both directly kill tumor cells and stimulate the immune system against solid tumors, led by ruxotemitide, a first-in-class oncolytic molecule in trials across multiple cancer indications as monotherapy and in combination with checkpoint inhibitors.
Average Trading Volume: 59,883
Current Market Cap: NOK788.2M
For detailed information about 6BG stock, go to TipRanks’ Stock Analysis page.